CMS Finalizes Mandatory MFN Drug Pricing Model for Medicare Part B

In a client alert, Skadden reports that CMS finalized the GLOBE Model, a mandatory Medicare Part B drug payment model implementing most-favored-nation pricing published September 30, 2026. The rule ties Part B drug reimbursement to the lowest prices paid by other economically comparable countries, affecting manufacturers and providers who bill for physician-administered drugs. The alert outlines the model's mechanics and the Trump administration's rationale for the MFN approach. While the model targets Medicare Part B specifically, its drug pricing benchmarks and provider payment methodology are frequently referenced in Medicaid drug pricing and rebate policy discussions.

Pharmacy · Finance